1. Home
  2. NVRO vs CCIA Comparison

NVRO vs CCIA Comparison

Compare NVRO & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVRO
  • CCIA
  • Stock Information
  • Founded
  • NVRO 2006
  • CCIA N/A
  • Country
  • NVRO United States
  • CCIA
  • Employees
  • NVRO N/A
  • CCIA N/A
  • Industry
  • NVRO Medical/Dental Instruments
  • CCIA
  • Sector
  • NVRO Health Care
  • CCIA
  • Exchange
  • NVRO Nasdaq
  • CCIA Nasdaq
  • Market Cap
  • NVRO 134.5M
  • CCIA N/A
  • IPO Year
  • NVRO 2014
  • CCIA 2023
  • Fundamental
  • Price
  • NVRO $3.84
  • CCIA $25.80
  • Analyst Decision
  • NVRO Hold
  • CCIA
  • Analyst Count
  • NVRO 14
  • CCIA 0
  • Target Price
  • NVRO $7.97
  • CCIA N/A
  • AVG Volume (30 Days)
  • NVRO 416.5K
  • CCIA N/A
  • Earning Date
  • NVRO 02-19-2025
  • CCIA N/A
  • Dividend Yield
  • NVRO N/A
  • CCIA N/A
  • EPS Growth
  • NVRO N/A
  • CCIA N/A
  • EPS
  • NVRO N/A
  • CCIA N/A
  • Revenue
  • NVRO $419,146,000.00
  • CCIA N/A
  • Revenue This Year
  • NVRO N/A
  • CCIA N/A
  • Revenue Next Year
  • NVRO $0.65
  • CCIA N/A
  • P/E Ratio
  • NVRO N/A
  • CCIA N/A
  • Revenue Growth
  • NVRO N/A
  • CCIA N/A
  • 52 Week Low
  • NVRO $3.52
  • CCIA N/A
  • 52 Week High
  • NVRO $21.74
  • CCIA N/A
  • Technical
  • Relative Strength Index (RSI)
  • NVRO 43.89
  • CCIA 44.76
  • Support Level
  • NVRO $3.60
  • CCIA $25.63
  • Resistance Level
  • NVRO $3.90
  • CCIA $25.85
  • Average True Range (ATR)
  • NVRO 0.28
  • CCIA 0.13
  • MACD
  • NVRO 0.01
  • CCIA -0.01
  • Stochastic Oscillator
  • NVRO 39.56
  • CCIA 35.14

About NVRO Nevro Corp.

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028

Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing primarily in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting primarily of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

Share on Social Networks: